RHS Financial LLC Takes Position in Gilead Sciences, Inc. $GILD

RHS Financial LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 2,108 shares of the biopharmaceutical company’s stock, valued at approximately $234,000.

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. Price T Rowe Associates Inc. MD boosted its position in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. Nuveen LLC acquired a new position in Gilead Sciences in the first quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC acquired a new position in Gilead Sciences in the second quarter valued at about $238,083,000. Los Angeles Capital Management LLC lifted its position in Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after buying an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after buying an additional 1,942,433 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.4%

Shares of NASDAQ:GILD opened at $117.18 on Monday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market capitalization of $145.40 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The firm’s 50-day moving average is $114.65 and its two-hundred day moving average is $110.25. Gilead Sciences, Inc. has a 1 year low of $84.17 and a 1 year high of $121.83.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period in the prior year, the firm earned $2.01 earnings per share. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares of the company’s stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 77,000 shares of company stock worth $8,853,430 over the last three months. Insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 8th. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research report on Friday, July 25th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Finally, Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $118.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.